Mpox Resurgence: New Outbreak in Guinea-Bissau Raises Alarm, Children Particularly Vulnerable

A fresh mpox outbreak in Guinea-Bissau, a nation previously untouched by the virus, has sent ripples of concern through the global health community. What sets this latest emergence apart is the alarming concentration of cases among young children, signaling a potential shift in transmission patterns and underscoring the enduring vulnerabilities within fragile health systems.

Quick summary

• Guinea-Bissau is experiencing its first mpox outbreak, with nearly half of all suspected cases reported in children under 15, primarily those under four years old.
• Mpox, previously endemic in parts of Africa, has evolved into a global concern since 2022, with two major international outbreaks affecting 145 countries.
• Experts highlight that young children face the highest risk of severe illness and mortality from mpox, although data bias in reporting may influence observed statistics.
• Despite the existence of effective vaccines, significant disparities persist in global distribution, impeding rapid responses in low-income settings where the need is greatest.

Why it matters

The reappearance of mpox in a new country, particularly with a significant impact on children, signifies a critical juncture in global health security. For individuals and communities, it means an elevated risk of a potentially severe disease, especially for the youngest and most vulnerable members of society. The heightened susceptibility of children to mpox underscores the urgent need for enhanced surveillance, diagnostic capabilities, and accessible supportive care in resource-constrained environments.

For the broader healthcare industry and policymakers, this outbreak serves as a stark reminder of the unpredictable nature of zoonotic diseases and the necessity for robust, equitable preparedness strategies. It highlights the systemic challenges in vaccine access, where high-income nations often secure initial supplies while low-income regions, frequently the epicenters of outbreaks, struggle. This disparity not only exacerbates health inequities but also allows viruses to establish new transmission chains, posing a continued threat to global stability.

Furthermore, the unlinked nature of reported cases in Guinea-Bissau suggests broader community transmission that remains undetected, placing additional pressure on already strained public health infrastructure. The lessons learned from previous mpox outbreaks – the importance of early detection, contact tracing, and comprehensive supportive care – are once again brought to the forefront, emphasizing that a multi-faceted approach, beyond just vaccines, is essential for effective containment.

Background

Mpox, a viral infection caused by a virus belonging to the Orthopoxvirus genus, first gained international notoriety during a global outbreak in 2022. Before this, the disease, historically known as monkeypox, was primarily confined to small, sporadic outbreaks in a handful of African countries where it was considered endemic. The name change to mpox, recommended by the World Health Organization (WHO), was a direct response to concerns that the original moniker was contributing to racist and stigmatizing language during the 2022 international spread.

The 2022 outbreak was predominantly driven by Clade II, also referred to as the West African clade, which demonstrated an increased efficiency in human-to-human transmission. This variant spread globally, largely through close sexual contact among men who have sex with men, prompting the WHO to declare a public health emergency of international concern in July 2022. This status was eventually lifted in May 2023, following extensive contact-tracing and vaccination efforts that helped curb the spread, totaling approximately 90,000 infections.

However, the global mpox challenge was far from over. In June 2024, researchers raised alarms about a new variant of Clade I, historically known as the Congo Basin clade, emerging in the Democratic Republic of the Congo (DRC). This new Clade I variant also exhibited enhanced human-to-human transmission capabilities, leading to another major international outbreak. Consequently, the WHO once again declared a public health emergency of international concern in August 2024, a status that was subsequently lifted in September 2025 as case numbers and deaths began to decline, indicating better control of the situation.

Throughout these two major global emergencies in 2022 and 2024, nearly 190,000 laboratory-confirmed cases of mpox were reported across 145 countries. This marked a significant departure from previous epidemiological patterns, firmly establishing mpox as a globally circulating pathogen with the capacity for sustained human-to-human chains of transmission. The US Centers for Disease Control and Prevention even suggested that mpox was on a path to becoming endemic within the United States, underscoring its established presence beyond traditional endemic regions.

Children at the Forefront of the Guinea-Bissau Outbreak

The current situation in Guinea-Bissau presents a particularly worrying dimension. Unicef has expressed significant concern over the demographic breakdown of suspected cases: out of 46 individuals, 23 were children under the age of 15, with the majority of these being under four years old. This pattern differs from previous global outbreaks which saw transmission primarily within specific adult networks.

Experts, such as Dr. Aula Abbara from Imperial College London, emphasize that young children are at a significantly higher risk of severe disease and death from mpox compared to healthy adults. Their developing immune systems make them more vulnerable to the virus's effects. Professor Michael Marks of the London School of Hygiene & Tropical Medicine adds that close physical contact among children and parents, combined with often cramped living conditions prevalent in settings like Guinea-Bissau, creates an ideal environment for efficient transmission.

While the data points to a high impact on children, Dr. Abbara also cautions that some bias might be present in the figures. Families in areas with fragile health systems are often more inclined to seek medical attention for a sick child than for an adult, potentially skewing the apparent over-representation of pediatric cases. Nevertheless, the underlying vulnerability of this age group remains a critical concern.

Addressing Transmission: From Contact to Community Spread

One of the challenges in Guinea-Bissau is that confirmed cases do not appear to be directly linked to one another. This absence of clear epidemiological connections suggests that the virus is circulating more broadly within the community, with many cases likely going undetected. Such community-level transmission complicates traditional contact tracing efforts and indicates a wider public health challenge.

Mpox spreads through close physical contact, a characteristic that allows it to adapt to various transmission contexts. While the 2022 global outbreak was largely confined to close sexual networks, subsequent outbreaks, particularly in regions like the DRC, have shown spread in settings with high population density, such as refugee camps or internally displaced person (IDP) sites where people live in close proximity. The situation in Guinea-Bissau, with its concentration in young children, points to household and community contact as a primary driver of transmission.

Vaccine Equity and Preparedness: An Ongoing Battle

The WHO recommends two vaccines for mpox, which can be administered to individuals at high risk of exposure or those who have been in close contact with a confirmed case to prevent further spread. However, the efficacy of these tools is severely hampered by stark global inequities in access.

Professor Marks highlights this persistent challenge: vaccine supplies are most abundant in high-income countries but remain critically scarce in low-income settings, precisely where the combination of high need and conducive conditions for transmission is most pronounced. This imbalance has historically plagued global health responses, from HIV to COVID-19, and continues to undermine efforts to contain emerging infectious diseases effectively.

A promising development on the horizon is the imminent launch of a new global mpox vaccine stockpile. This initiative aims to facilitate the more rapid deployment of vaccines to outbreak zones and, crucially, to provide manufacturers with a clear, concrete demand signal, encouraging increased production. Such stockpiles are vital for ensuring that resources can be mobilized quickly to quell outbreaks before they escalate into larger epidemics.

The Role of Therapeutics and Supportive Care

Beyond vaccination, therapeutic options for mpox remain somewhat limited. Clinical trials for the antiviral drug tecovirimat, conducted on patients with mpox Clade I in the DRC, did not demonstrate superior efficacy compared to a placebo. While its potential benefit for specific patient populations, such as immunocompromised individuals (e.g., those living with HIV), is still under investigation, its broad utility as a primary treatment is questionable.

Crucially, the same trial in the DRC underscored the profound impact of basic supportive care. Providing patients with essential medical attention, including hydration, pain management, and wound care, dramatically improved their chances of survival. Dr. Abbara stresses that while vaccines are invaluable for prevention, outbreaks are not controlled by vaccines alone. Early detection, robust contact tracing, comprehensive supportive care, and strong public health surveillance remain absolutely critical for understanding and containing any mpox resurgence.

Qnews24h insight

The mpox outbreak in Guinea-Bissau, particularly its disproportionate impact on children, serves as a sobering reminder of the interconnectedness of global health and the persistent challenges in achieving true health equity. While global health emergencies declared in 2022 and 2024 successfully brought mpox into the international spotlight and spurred vaccine development, the current situation reveals critical gaps in sustained preparedness and equitable resource distribution. The fact that a new variant of Clade I has emerged with enhanced transmissibility, coupled with the virus appearing in previously unaffected regions, suggests an evolving pathogen that demands continuous vigilance. The unequal access to vaccines, where the highest need often meets the lowest supply, remains a foundational vulnerability. This disparity not only leaves the most vulnerable populations exposed but also creates fertile ground for new transmission pathways and potential endemicity in areas ill-equipped to cope. Moving forward, global health strategies must prioritize not just rapid response mechanisms but also long-term investments in strengthening primary healthcare infrastructure, equitable vaccine procurement, and community-level surveillance in all nations, irrespective of their economic standing, to truly break the cycle of reactive crisis management.

Sources

• The Guardian

FAQ

1. What is mpox and how does it spread?
   Mpox, formerly known as monkeypox, is an infectious disease caused by a virus related to smallpox. It typically starts with flu-like symptoms, followed by a distinctive rash of fluid-filled blisters that scab over. It spreads through close physical contact, which can include sexual contact, direct contact with lesions, respiratory droplets during prolonged face-to-face contact, and contact with contaminated materials like bedding.
2. Why are children particularly vulnerable in the new mpox outbreak?
   Young children are at the highest risk of severe disease and death from mpox because their immune systems are still developing. Additionally, in many communities, children have frequent close physical contact with family members and other children, often living in cramped conditions, which increases the likelihood of transmission.
3. What are the main challenges in controlling mpox outbreaks globally?
   Key challenges include unequal access to mpox vaccines, with supplies concentrated in high-income countries while low-income settings, where outbreaks often originate, face severe shortages. Other challenges include late detection of cases, difficulties in comprehensive contact tracing, and the need for stronger overall public health surveillance and basic supportive care infrastructure in vulnerable regions.